# LUPER (NCT04358237)

> Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04358237
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Antonio Calles Blanco
- Conditions: Small Cell Lung Carcinoma
- Interventions: Lurbinectedin; Pembrolizumab
- Enrollment: 28
- Primary outcome: Phase I: Maximum tolerated dose (MTD) and recommended phase II dose (RD) of lurbinectedin in combination with pembrolizumab in patients with relapsed SCLC.
- Primary outcome: Phase II: Efficacy of lurbinectedin in combination with pembrolizumab in terms of overall response rate (ORR), according to RECIST 1.1, in patients with relapsed SCLC.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 18
- YouTube: 2
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=luper-nct04358237

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04358237", "email": "<work email>"}; the inbox owner confirms by the emailed link.